Navigation Links
Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Date:11/27/2008

SEATTLE, Nov. 28 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the agreement with Spectrum Pharmaceuticals of Irvine, California to jointly market and develop Zevalin(R).

    Conference Call Numbers
    Monday, December 1
    8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
    1-800-219-6110 (US Participants)
    1-303-262-2053 (International)

    Call-back numbers for post-listening available at 11:30 a.m. Eastern:
    1-800-405-2236 (US Participants)
    1-303-590-3000 (International)
    Passcode: 11123066#

Live audio webcast at www.celltherapeutics.com will be archived for post listening approximately two hours after call ends

    Slides for the webcast can be accessed at:
http://www.celltherapeutics.com/investor_updates


    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: media@ctiseattle.com
    www.celltherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
2. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
3. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
4. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
5. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
6. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
7. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
8. Cell Therapeutics, Inc. Announces Reverse Stock Split
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
11. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... announced the formation of its Medical/Clinical Advisory Board. ... industry veterans who enhance the range and depth ... development of its novel prenatal diagnostic tests.  These ... and strategic guidance for the company,s product development ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, is ... fully 21 CFR Part 11-compliant email client designed to provide product vigilance departments ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical ... update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data ... the existing policy. AMIA recommended that NIH earmark funding for researchers to produce ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
Breaking Biology News(10 mins):